Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

NCT ID: NCT01694485

Last Updated: 2019-06-27

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 359 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-16
• Study Completion Date: 2018-04-10

Brief Summary

The primary objective of this study is to evaluate the effect of abrilumab on induction of remission in adults with moderate to severe ulcerative colitis after 8 weeks of treatment as assessed by a total Mayo Score ≤ 2 points, with no individual subscore > 1 point.

Detailed Description

The study consisted of a 24-week double-blind, placebo-controlled treatment period followed by an open-label period of approximately 108 weeks. Participants were eligible to enter the open-label period of the study early if they did not achieve a response at week 8 and had an inadequate response at week 12 or later or if they experienced disease worsening after achieving response and/or remission at week 8. Failure to achieve response at week 8 was defined as failure to achieve a decrease from baseline in total Mayo Score ≥ 3 points and ≥ 30% decrease from baseline. Inadequate response at week 12 or later was defined as failure to achieve a 2-point decrease and 25% improvement in partial Mayo Score compared with screening and minimum partial Mayo Score ≥ 5 points. Disease worsening was defined as an increase in partial Mayo Score ≥ 3 points from the week 8 value and minimum partial Mayo Score ≥ 5 points with recto-sigmoidoscopy sub-score ≥ 2.

Participants were planned to be randomized in a 2:1:2:2:2 ratio to placebo or abrilumab at 7 mg, 21 mg, 70 mg (on day 1, week 2, week 4, and every 4 weeks thereafter until week 24), or 210 mg (on day 1 followed by placebo in weeks 2 and 4 and every 4 weeks thereafter until week 24), respectively. Due to a consistent discrepancy between the investigational product (IP) instruction manual (IPIM) description of vial positions and the actual vial positions in the IP package participants were initially randomized to 3 arms (placebo, 70 mg, and 210 mg) with a randomization ratio of 4:3:2. The study was temporarily paused while this issue was investigated. Once the discrepancy was corrected, Protocol Amendment 3 implemented, and affected participants completed their double-blind treatment period, the study resumed enrollment and randomization per protocol. Neither the randomization nor study blind was compromised and therefore the intent-to-treat principle was maintained.

Conditions

Ulcerative Colitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Placebo Q4W/Abrilumab 210 mg Q3M

Participants received placebo by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.

During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.

Group Type: PLACEBO_COMPARATOR

Abrilumab

Intervention Type: BIOLOGICAL

Administered by subcutaneous injection.

Placebo

Intervention Type: DRUG

Placebo matching to abrilumab administered by subcutaneous injection

Abrilumab 7 mg Q4W/Abrilumab 210 mg Q3M

Participants received 7 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks (Q4W) thereafter until week 24.

During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.

Group Type: EXPERIMENTAL

Abrilumab

Intervention Type: BIOLOGICAL

Administered by subcutaneous injection.

Abrilumab 21 mg Q4W/Abrilumab 210 mg Q3M

Participants received 21 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.

During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.

Group Type: EXPERIMENTAL

Abrilumab

Intervention Type: BIOLOGICAL

Administered by subcutaneous injection.

Abrilumab 70 mg Q4W/Abrilumab 210 mg Q3M

Participants received 70 mg abrilumab by subcutaneous injection on day 1, week 2, week 4, and every 4 weeks thereafter until week 24.

During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.

Group Type: EXPERIMENTAL

Abrilumab

Intervention Type: BIOLOGICAL

Administered by subcutaneous injection.

Abrilumab 210 mg/Abrilumab 210 mg Q3M

Participants received a single dose of 210 mg abrilumab by subcutaneous injection on day 1, followed by placebo at week 2, week 4, and every 4 weeks thereafter until week 24.

During the open-label period, participants received abrilumab 210 mg once every 3 months (Q3M) for 108 weeks.

Group Type: EXPERIMENTAL

Abrilumab

Intervention Type: BIOLOGICAL

Administered by subcutaneous injection.

Placebo

Intervention Type: DRUG

Placebo matching to abrilumab administered by subcutaneous injection

Interventions

Abrilumab

Administered by subcutaneous injection.

Intervention Type: BIOLOGICAL

Placebo

Placebo matching to abrilumab administered by subcutaneous injection

Intervention Type: DRUG

Other Intervention Names

AMG 181

Eligibility Criteria

Inclusion Criteria

• Diagnosis of ulcerative colitis (UC) established ≥ 3 months before baseline by clinical and endoscopic evidence and corroborated by a histopathology report.
• Moderate to severe active UC as defined by a total Mayo score of 6 to 12 with a centrally read rectosigmoidoscopy score ≥2 prior to baseline
• Inadequate response to, loss of response to, or intolerance to at least one of the following treatments:

• Immunomodulators
• Anti-TNF agents
• Corticosteroids (non-US sites only).
• Neurological exam free of clinically significant, unexplained signs or symptoms during screening and no clinically significant change prior to randomization

Exclusion Criteria

• Disease limited to the rectum (ie, within 10 cm of the anal verge)
• Toxic megacolon
• Crohn's Disease
• History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, or ileostomy for UC
• Planned bowel surgery within 24 weeks from baseline
• Stool positive for C. Difficile toxin at screening
• History of gastrointestinal surgery within 8 weeks of baseline
• Primary Sclerosing Cholangitis
• Any uncontrolled or clinically significant systemic disease
• Condition or disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with study evaluation, procedures or completion.
• Known to have tested positive for hepatitis B virus surface antigen, hepatitis C virus antibody or human immunodeficiency virus (HIV)
• Underlying condition that predisposes subject to infections (eg, uncontrolled diabetes; history of splenectomy)
• Known history of drug or alcohol abuse within 1 year of screening
• Malignancy (other than resected cutaneous basal or cutaneous squamous cell carcinoma, or treated in situ cervical cancer considered cured) within 5 years of screening visit (if a malignancy occurred > 5 years ago, subject is eligible with documentation of disease free state since treatment)
• Immunosuppressive therapy with either cyclosporine A, tacrolimus, or mycophenolate mofetil, within 1 month prior to baseline
• Prior exposure to anti tumor necrosis factor (TNF) agents, within 2 months, or 5 times the respective elimination half life (whichever is longer) prior to baseline
• Any prior exposure to vedolizumab, rituximab, efalizumab, natalizumab
• Use of topical (rectal) aminosalicylic acid (eg, mesalamine) or topical (rectal) steroids within 2 weeks prior to baseline
• Use of intravenous or intramuscular corticosteroids within 2 weeks prior to screening and during screening
• Previously treated with AMG 181
• Received any type of live attenuated vaccine < 1 month prior to baseline or is planning to receive any such live attenuated vaccine over the course of the study
• Treatment of infection with intravenous (within 30 days of baseline) or oral (within 14 days prior to baseline) antibiotics, antivirals, or antifungals
• Abnormal laboratory results at screening
• Any other laboratory abnormality, which, in the opinion of the investigator, will prevent the subject from completing the study or will interfere with the interpretation of the study results
• Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational agent(s)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Amgen

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

MD

Role: STUDY_DIRECTOR

Amgen

Locations

Research Site

Birmingham, Alabama, United States

Research Site

Dothan, Alabama, United States

Research Site

Mobile, Alabama, United States

Research Site

Scottsdale, Arizona, United States

Research Site

La Jolla, California, United States

Research Site

Torrance, California, United States

Research Site

Lone Tree, Colorado, United States

Research Site

Jacksonville, Florida, United States

Research Site

Miami, Florida, United States

Research Site

Naples, Florida, United States

Research Site

Atlanta, Georgia, United States

Research Site

Arlington Heights, Illinois, United States

Research Site

Urbana, Illinois, United States

Research Site

Hammond, Louisiana, United States

Research Site

Chesterfield, Michigan, United States

Research Site

Rochester, Minnesota, United States

Research Site

Great Neck, New York, United States

Research Site

New York, New York, United States

Research Site

Charlotte, North Carolina, United States

Research Site

Greenville, North Carolina, United States

Research Site

Mentor, Ohio, United States

Research Site

Germantown, Tennessee, United States

Research Site

San Antonio, Texas, United States

Research Site

Seattle, Washington, United States

Research Site

Seattle, Washington, United States

Research Site

Bankstown, New South Wales, Australia

Research Site

Concord, New South Wales, Australia

Research Site

Adelaide, South Australia, Australia

Research Site

Box Hill, Victoria, Australia

Research Site

Innsbruck, , Austria

Research Site

Sankt Veit an der Glan, , Austria

Research Site

Vienna, , Austria

Research Site

Bonheiden, , Belgium

Research Site

Brussels, , Belgium

Research Site

Brussels, , Belgium

Research Site

Ghent, , Belgium

Research Site

Leuven, , Belgium

Research Site

Liège, , Belgium

Research Site

Calgary, Alberta, Canada

Research Site

Vancouver, British Columbia, Canada

Research Site

Vancouver, British Columbia, Canada

Research Site

Winnipeg, Manitoba, Canada

Research Site

Kingston, Ontario, Canada

Research Site

London, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Hradec Králové, , Czechia

Research Site

Prague, , Czechia

Research Site

Prague, , Czechia

Research Site

Ústí nad Labem, , Czechia

Research Site

Aalborg, , Denmark

Research Site

Århus C, , Denmark

Research Site

Herlev, , Denmark

Research Site

Hvidovre, , Denmark

Research Site

Køge, , Denmark

Research Site

Odense C, , Denmark

Research Site

Tallinn, , Estonia

Research Site

Tallinn, , Estonia

Research Site

Tartu, , Estonia

Research Site

Amiens, , France

Research Site

Caen, , France

Research Site

Lille, , France

Research Site

Nice, , France

Research Site

Paris, , France

Research Site

Pessac, , France

Research Site

Toulouse, , France

Research Site

Vandœuvre-lès-Nancy, , France

Research Site

Berlin, , Germany

Research Site

Berlin, , Germany

Research Site

Frankfurt am Main, , Germany

Research Site

Halle, , Germany

Research Site

Heidelberg, , Germany

Research Site

Kiel, , Germany

Research Site

Athens, , Greece

Research Site

Haidari, , Greece

Research Site

Heraklion, , Greece

Research Site

Larissa, , Greece

Research Site

Piraeus, , Greece

Research Site

Békéscsaba, , Hungary

Research Site

Budapest, , Hungary

Research Site

Budapest, , Hungary

Research Site

Debrecen, , Hungary

Research Site

Miskolc, , Hungary

Research Site

Miskolc, , Hungary

Research Site

Pécs, , Hungary

Research Site

Szeged, , Hungary

Research Site

Szekszárd, , Hungary

Research Site

Bologna, , Italy

Research Site

Florence, , Italy

Research Site

Milan, , Italy

Research Site

Padua, , Italy

Research Site

Roma, , Italy

Research Site

Rozzano MI, , Italy

Research Site

Riga, , Latvia

Research Site

Riga, , Latvia

Research Site

Amsterdam, , Netherlands

Research Site

Breda, , Netherlands

Research Site

Leiden, , Netherlands

Research Site

Maastricht, , Netherlands

Research Site

Rotterdam, , Netherlands

Research Site

Oslo, , Norway

Research Site

Tromsø, , Norway

Research Site

Bialystok, , Poland

Research Site

Bydgoszcz, , Poland

Research Site

Lodz, , Poland

Research Site

Lodz, , Poland

Research Site

Lodz, , Poland

Research Site

Warsaw, , Poland

Research Site

Moscow, , Russia

Research Site

Nizhny Novgorod, , Russia

Research Site

Saint Petersburg, , Russia

Research Site

Samara, , Russia

Research Site

St.-Petrsburg, , Russia

Research Site

Stavropol, , Russia

Research Site

Basel, , Switzerland

Research Site

Bern, , Switzerland

Research Site

Zurich, , Switzerland

Research Site

Birmingham, , United Kingdom

Research Site

Blackpool, , United Kingdom

Research Site

Coventry, , United Kingdom

Research Site

Derby, , United Kingdom

Research Site

London, , United Kingdom

Research Site

Manchester, , United Kingdom

Research Site

Norwich, , United Kingdom

Countries

United States; Australia; Austria; Belgium; Canada; Czechia; Denmark; Estonia; France; Germany; Greece; Hungary; Italy; Latvia; Netherlands; Norway; Poland; Russia; Switzerland; United Kingdom

References

Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV Jr, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019 Mar;156(4):946-957.e18. doi: 10.1053/j.gastro.2018.11.035. Epub 2018 Nov 23.

Reference Type: DERIVED

PMID: 30472236 (View on PubMed)

Related Links

http://www.amgentrials.com

AmgenTrials clinical trials website

Other Identifiers

2011-005251-13

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

20110166

Identifier Type: -

Identifier Source: org_study_id